E Livingstone
Overview
Explore the profile of E Livingstone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schirren A, Albrecht J, Melchers S, Weiss C, Buttner S, Dippel E, et al.
J Eur Acad Dermatol Venereol
. 2024 Jan;
38(5):954-966.
PMID: 38279594
Background: Primary cutaneous B-cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%-30% of all primary cutaneous lymphomas (PCL). Previous studies revealed impaired health-related quality...
2.
Livingstone E, Gogas H, Kandolf-Sekulovic L, Meier F, Eigentler T, Ziemer M, et al.
Eur J Cancer
. 2023 Jul;
190:112941.
PMID: 37482012
Aim: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous...
3.
Kahler K, Huning S, Nashan D, Meiss F, Rafei-Shamsabadi D, Rissmann H, et al.
J Cancer Res Clin Oncol
. 2023 Jul;
149(13):11705-11718.
PMID: 37405475
Purpose: Adjuvant treatment with immune checkpoint inhibitors like PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT) in high-risk melanoma patients demonstrate a significant improvement in disease-free...
4.
Jansen P, Lodde G, Wetter A, Welt A, Stuschke M, Duhrsen U, et al.
J Eur Acad Dermatol Venereol
. 2021 Dec;
36 Suppl 1:41-44.
PMID: 34855243
Cutaneous squamous cell carcinoma (cSCC) numbers among the most common types of skin cancer and is known as one of the cancer entities with the highest mutational burden among all...
5.
Jansen P, Lodde G, Griewank K, Hadaschik E, Roesch A, Ugurel S, et al.
J Eur Acad Dermatol Venereol
. 2021 Dec;
36 Suppl 1:29-34.
PMID: 34855242
Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma are the most common types of skin cancer. For patients with locally advanced and metastatic cSCC, the programmed cell death 1...
6.
Hassel J, Livingstone E, Allam J, Behre H, Bojunga J, Klein H, et al.
ESMO Open
. 2021 Aug;
6(5):100248.
PMID: 34438241
Melanoma is one of the most common cancers in adolescents and adults at fertile age, especially in women. With novel and more effective systemic therapies that began to profoundly change...
7.
Albrecht M, Hadaschik E, Zimmer L, Livingstone E, Hamacher R, Bauer S, et al.
Hautarzt
. 2021 Jan;
72(9):801-804.
PMID: 33439269
We report a case of a 75-year-old man with facial edema that also affected the periorbital area who was admitted to the hospital with the suspected diagnosis of Quincke's edema....
8.
Zaremba A, Zimmer L, Griewank K, Ugurel S, Roesch A, Schadendorf D, et al.
Internist (Berl)
. 2020 May;
61(7):669-675.
PMID: 32462249
Although cutaneous melanoma accounts for only about 4% of all skin cancers (including nonmelanocytic skin cancer), it is responsible for 80% of all deaths caused by skin cancer. The introduction...
9.
Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, et al.
Br J Dermatol
. 2020 Feb;
183(5):928-939.
PMID: 32064597
Background: GNAQ and GNA11 mutant nonuveal melanoma represent a poorly characterized rare subgroup of melanoma with a gene mutation profile similar to uveal melanoma. Objectives: To characterize these tumours in...
10.
Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, et al.
Ann Oncol
. 2020 Jan;
31(1):144-152.
PMID: 31912789
Background: Programmed cell death protein 1 (PD-1) checkpoint inhibition has recently advanced to one of the most effective treatment strategies in melanoma. Nevertheless, a considerable proportion of patients show upfront...